Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of October 2016, with a report date of October 25, 2016. The company is a foreign private issuer based in Rehovot, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is a departure in senior management:
- Chief Financial Officer: Mr. Eyal Leibovitz has mutually agreed with the Company to end his service as CFO on December 31, 2016.
- Succession: The Company has initiated an external search for a successor to Mr. Leibovitz.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The unusual item noted is the scheduled departure of the CFO, which may impact financial reporting continuity until a successor is appointed.
Key Facts for Investor Verification
- Confirm the timeline for the appointment of a new CFO following the December 31, 2016 departure of Mr. Leibovitz.
- Verify if the CFO departure coincides with any undisclosed financial challenges or strategic shifts.
- Monitor subsequent filings for the appointment of an interim or permanent CFO.